After today’s announcement, BRL/Pliva may be the prototype for the future of generics. BRL CEO Bruce Downey says that, when the merger closes, BRL will be the clear #1 in biogenerics and will have vertical integration and low-cost (and low-tax) manufacturing that rivals anyone, including TEVA.
Market Data 
Markets 
